These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22785114)

  • 41. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
    Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT;
    JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease.
    Fassett RG; Coombes JS; Packham D; Fairley KF; Kincaid-Smith P
    Scand J Urol Nephrol; 2010 Feb; 44(1):56-61. PubMed ID: 20034362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
    Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Risk D; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):112-20. PubMed ID: 17699395
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.
    Kim SH; Chung WY; Zo JH; Kim MA; Chang HJ; Cho YS; Youn TJ; Chae IH; Choi DJ; Gwak JJ; Lee HY; Park JS; Kang HJ; Kim YJ; Kim HS
    Clin Ther; 2009 May; 31(5):988-98. PubMed ID: 19539099
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
    Caroli A; Perico N; Perna A; Antiga L; Brambilla P; Pisani A; Visciano B; Imbriaco M; Messa P; Cerutti R; Dugo M; Cancian L; Buongiorno E; De Pascalis A; Gaspari F; Carrara F; Rubis N; Prandini S; Remuzzi A; Remuzzi G; Ruggenenti P;
    Lancet; 2013 Nov; 382(9903):1485-95. PubMed ID: 23972263
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease.
    Panizo N; Goicoechea M; García de Vinuesa S; Arroyo D; Yuste C; Rincón A; Verdalles U; Ruiz-Caro C; Quiroga B; Luño J
    Nefrologia; 2012; 32(2):197-205. PubMed ID: 22425799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
    Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
    J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Schrier RW
    J Am Soc Nephrol; 2009 Sep; 20(9):1888-93. PubMed ID: 19696226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria.
    Peces R; Aguilar A; Vega C; Cuesta E; Peces C; Selgas R
    Nefrologia; 2012; 32(2):160-5. PubMed ID: 22425801
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study.
    Pankewycz O; Leca N; Kohli R; Weber-Shrikant E; Said M; Alnimri M; Feng L; Patel S; Laftavi MR
    Transplant Proc; 2011 Mar; 43(2):519-23. PubMed ID: 21440749
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.
    Seliger SL; Abebe KZ; Hallows KR; Miskulin DC; Perrone RD; Watnick T; Bae KT
    Am J Nephrol; 2018; 47(5):352-360. PubMed ID: 29779024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma.
    Di Paolo S; Teutonico A; Ranieri E; Gesualdo L; Schena PF
    Am J Kidney Dis; 2007 Mar; 49(3):462-70. PubMed ID: 17336708
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized intervention studies in human polycystic kidney and liver disease.
    Schrier RW
    J Am Soc Nephrol; 2010 Jun; 21(6):891-3. PubMed ID: 20431043
    [No Abstract]   [Full Text] [Related]  

  • 55. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
    Meijer E; Drenth JP; d'Agnolo H; Casteleijn NF; de Fijter JW; Gevers TJ; Kappert P; Peters DJ; Salih M; Soonawala D; Spithoven EM; Torres VE; Visser FW; Wetzels JF; Zietse R; Gansevoort RT;
    Am J Kidney Dis; 2014 Mar; 63(3):446-55. PubMed ID: 24342522
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.
    Bae KT; Zhu F; Chapman AB; Torres VE; Grantham JJ; Guay-Woodford LM; Baumgarten DA; King BF; Wetzel LH; Kenney PJ; Brummer ME; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
    Clin J Am Soc Nephrol; 2006 Jan; 1(1):64-9. PubMed ID: 17699192
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Autosomal dominant polycystic kidney disease].
    Horie S
    Nihon Jinzo Gakkai Shi; 2011; 53(1):6-9. PubMed ID: 21370570
    [No Abstract]   [Full Text] [Related]  

  • 58. Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis.
    Lin CH; Chao CT; Wu MY; Lo WC; Lin TC; Wu MS
    Int Urol Nephrol; 2019 Nov; 51(11):2015-2025. PubMed ID: 31578673
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre.
    Thong KM; Ong AC
    QJM; 2013 Jul; 106(7):639-46. PubMed ID: 23587574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor.
    Siroky BJ; Towbin AJ; Trout AT; Schäfer H; Thamann AR; Agricola KD; Tudor C; Capal J; Dixon BP; Krueger DA; Franz DN
    J Pediatr; 2017 Aug; 187():318-322.e2. PubMed ID: 28600153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.